OPKO Health (OPK) to Release Earnings on Tuesday

OPKO Health (NASDAQ:OPK) is expected to issue its quarterly earnings data after the market closes on Tuesday, February 25th. Analysts expect OPKO Health to post earnings of ($0.08) per share and revenue of $155.42 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

OPKO Health Trading Down 1.2 %

Shares of OPK stock opened at $1.64 on Tuesday. OPKO Health has a 12-month low of $0.86 and a 12-month high of $1.76. The company has a market capitalization of $1.12 billion, a PE ratio of -8.63 and a beta of 1.63. The firm has a 50 day moving average price of $1.53 and a two-hundred day moving average price of $1.53. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on OPK shares. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research report on Wednesday, January 8th.

Insider Activity

In other news, CEO Phillip Md Et Al Frost bought 199,072 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was bought at an average cost of $1.53 per share, for a total transaction of $304,580.16. Following the transaction, the chief executive officer now owns 211,911,477 shares of the company’s stock, valued at $324,224,559.81. This represents a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders acquired 1,621,609 shares of company stock worth $2,472,710. Corporate insiders own 47.26% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.